Literature DB >> 19124364

Role of phosphodiesterases in modulation of BKCa channels in hypertensive pulmonary arterial smooth muscle.

Shu Zhu1, Richard E White, Scott A Barman.   

Abstract

BKCa channels regulate pulmonary arterial pressure, and protein kinase C (PKC) inhibits BK(Ca) channels, but little is known about PKC-mediated modulation of BKCa channel activity in pulmonary arterial smooth muscle. Studies were carried out to determine mechanisms of PKC modulation of BKCa channel activity in pulmonary arterial smooth muscle cells (PASMC) of the fawn-hooded rat (FHR), an animal model of pulmonary hypertension. Forskolin opened BKCa channels in FHR PASMC, which was blocked by PKC activation, and reversed by the phosphodiesterase (PDE) inhibitors IBMX, milrinone, and zaprinast. PDE inhibition also blocked the vasoconstrictor response to PKC activation in FHR pulmonary arteries. These results indicate that PKC inhibits cAMP-induced activation of BKCa channels and causes pulmonary vasoconstriction in hypertensive pulmonary arterial smooth muscle via PDE, which further suggests PDE inhibitors for treatment of pulmonary hypertension.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19124364      PMCID: PMC4019332          DOI: 10.1177/1753465808091327

Source DB:  PubMed          Journal:  Ther Adv Respir Dis        ISSN: 1753-4658            Impact factor:   4.031


  48 in total

1.  Sildenafil citrate therapy for pulmonary arterial hypertension.

Authors:  Nazzareno Galiè; Hossein A Ghofrani; Adam Torbicki; Robyn J Barst; Lewis J Rubin; David Badesch; Thomas Fleming; Tamiza Parpia; Gary Burgess; Angelo Branzi; Friedrich Grimminger; Marcin Kurzyna; Gérald Simonneau
Journal:  N Engl J Med       Date:  2005-11-17       Impact factor: 91.245

2.  Milrinone attenuates serotonin-induced pulmonary hypertension and bronchoconstriction in dogs.

Authors:  E Hashiba; K Hirota; H Yoshioka; Y Hashimoto; T Kudo; T Sato; A Matsuki
Journal:  Anesth Analg       Date:  2000-04       Impact factor: 5.108

3.  sGC and PDE5 are elevated in lambs with increased pulmonary blood flow and pulmonary hypertension.

Authors:  S M Black; L S Sanchez; E Mata-Greenwood; J M Bekker; R H Steinhorn; J R Fineman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2001-11       Impact factor: 5.464

4.  Involvement of cGMP-dependent protein kinase in the relaxation of ovine pulmonary arteries to cGMP and cAMP.

Authors:  S N Dhanakoti; Y Gao; M Q Nguyen; J U Raj
Journal:  J Appl Physiol (1985)       Date:  2000-05

5.  Protein kinase C modulates Ca2+-activated K+ channels in cultured rat mesenteric artery smooth muscle cells.

Authors:  K Taguchi; K Kaneko; T Kubo
Journal:  Biol Pharm Bull       Date:  2000-12       Impact factor: 2.233

6.  Combined therapy with zaprinast and inhaled nitric oxide abolishes hypoxic pulmonary hypertension.

Authors:  J Nagamine; L L Hill; R G Pearl
Journal:  Crit Care Med       Date:  2000-07       Impact factor: 7.598

7.  Potassium (BK(Ca)) currents are reduced in microvascular smooth muscle cells from insulin-resistant rats.

Authors:  Christiana Dimitropoulou; Guichun Han; Allison W Miller; Mariela Molero; Leslie C Fuchs; Richard E White; Gerald O Carrier
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-03       Impact factor: 4.733

8.  Protein kinase C inhibits BKCa channel activity in pulmonary arterial smooth muscle.

Authors:  Scott A Barman; Shu Zhu; Richard E White
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2003-09-26       Impact factor: 5.464

9.  cAMP activates BKCa channels in pulmonary arterial smooth muscle via cGMP-dependent protein kinase.

Authors:  Scott A Barman; Shu Zhu; Guichan Han; Richard E White
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2003-01-24       Impact factor: 5.464

10.  Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension.

Authors:  A Sebkhi; Julian W Strange; Steven C Phillips; John Wharton; Martin R Wilkins
Journal:  Circulation       Date:  2003-06-09       Impact factor: 29.690

View more
  5 in total

1.  MicroRNA-mediated downregulation of K+ channels in pulmonary arterial hypertension.

Authors:  Aleksandra Babicheva; Ramon J Ayon; Tengteng Zhao; Jose F Ek Vitorin; Nicole M Pohl; Aya Yamamura; Hisao Yamamura; Brooke A Quinton; Manqing Ba; Linda Wu; Keeley S Ravellette; Shamin Rahimi; Francesca Balistrieri; Angela Harrington; Rebecca R Vanderpool; Patricia A Thistlethwaite; Ayako Makino; Jason X-J Yuan
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-09-25       Impact factor: 5.464

Review 2.  Protein Kinase C as Regulator of Vascular Smooth Muscle Function and Potential Target in Vascular Disorders.

Authors:  H C Ringvold; R A Khalil
Journal:  Adv Pharmacol       Date:  2016-07-18

Review 3.  Molecular pathogenesis and current pathology of pulmonary hypertension.

Authors:  Vinicio A de Jesus Perez
Journal:  Heart Fail Rev       Date:  2016-05       Impact factor: 4.214

Review 4.  Evolving mechanisms of vascular smooth muscle contraction highlight key targets in vascular disease.

Authors:  Zhongwei Liu; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2018-02-13       Impact factor: 5.858

5.  Milrinone relaxes pulmonary veins in guinea pigs and humans.

Authors:  Annette D Rieg; Said Suleiman; Alberto Perez-Bouza; Till Braunschweig; Jan W Spillner; Thomas Schröder; Eva Verjans; Gereon Schälte; Rolf Rossaint; Stefan Uhlig; Christian Martin
Journal:  PLoS One       Date:  2014-01-31       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.